Free Trial
NASDAQ:VYNE

VYNE Therapeutics Q3 2023 Earnings Report

VYNE Therapeutics logo
$0.96 -0.01 (-1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$0.99 +0.03 (+2.80%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VYNE Therapeutics EPS Results

Actual EPS
-$1.85
Consensus EPS
-$0.76
Beat/Miss
Missed by -$1.09
One Year Ago EPS
N/A

VYNE Therapeutics Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$0.15 million
Beat/Miss
Missed by -$40.00 thousand
YoY Revenue Growth
N/A

VYNE Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

VYNE Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Friday, August 8, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

VYNE Therapeutics Earnings Headlines

Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More VYNE Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VYNE Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VYNE Therapeutics and other key companies, straight to your email.

About VYNE Therapeutics

VYNE Therapeutics (NASDAQ:VYNE), a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View VYNE Therapeutics Profile

More Earnings Resources from MarketBeat